Airway Therapeutics

  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact

Airway Therapeutics Featured in Drug Discovery News

August 17, 2023 By Meghan Riley

Neonatal drug development comes out of the Dark Ages Left out of clinical trials for years, preterm infants have very few drugs developed just for them. Regulators, industry, and neonatologists plan to fix that. Read more: Drug Discovery News July/August 2023 or  PDF  

Filed Under: Media, News

Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

June 5, 2023 By Meghan Riley

Favorable safety profile confirmed also in fourth and final cohort including babies born at earliest gestational age of 23 to 24 weeks Interim analysis is complete and full results are expected by October 2023 Company expects to begin a Phase 3 trial by end of 2023 ATLANTA, GEORGIA (June 5, 2023) – Airway Therapeutics, Inc., …

Filed Under: News, Press Releases

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

April 11, 2023 By Meghan Riley

DSMC finds no safety concerns, allows use of highest dose for continued administration. Interim analysis of the trial expected in next month Company opens Spanish subsidiary to lead EU clinical trials ATLANTA, GEORGIA (April 11, 2023) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury …

Filed Under: Media, Press Releases

Airway Therapeutics Joins C-Path’s International Neonatal Consortium

February 16, 2023 By Meghan Riley

TUCSON, Ariz., February 15, 2023 — Critical Path Institute (C-Path) today announced that Airway Therapeutics, Inc. (“Airway”) has become a member of its International Neonatal Consortium (INC). Airway is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases. Airway is …

Filed Under: Media, News, Press Releases

Characterization of Oligomer Formation of Surfactant Protein-D (SP-D) Using AF4-MALLS

February 7, 2023 By Meghan Riley

Authors: Ryan R. Manning, Ryan E. Holcomb, Derrick S. Katayama, Giovanni M. Pauletti, Shawn N. Grant, Jan S. Rosenbaum, and Mark Cornell Manning Characterization of Oligomer Formation of Surfactant Protein-D (SP-D) Using AF4-MALLS Abstract: Background: Surfactant protein-S (SP-D) is a naturally occurring lung protein with the potential to treat pulmonary infections. A recombinant surfactant protein-D (SP-D) has …

Filed Under: News, Scientific Publications

logo

Airway Therapeutics, Inc

1200 Johnson Ferry Rd, Suite 300
Marietta, GA 30068

513.770.9630

  • Privacy

Sitemap

  • Home
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact
Copyright © 2015 Airway Therapeutics, Inc. All Rights Reserved.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
MENU
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact